Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - meloksikamas - oxicams - horses; dogs; cattle; cats; pigs; guinea pigs - katės:mažinimui lengvas ar vidutinio sunkumo pooperacinį skausmą ir uždegimą, po chirurginių procedūrų, e. ortopedijos ir minkštųjų audinių chirurgija. palengvinti skausmą ir uždegimą, ūminis ir lėtinis raumenų ir kaulų sistemos sutrikimai. sumažinti pooperacinį skausmą po ovariohysterectomy ir nedideli minkštųjų audinių chirurgija. cattle:for use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. vartoti kartu su peroraliniu rehidracijos gydymu viduriu, kad sumažėtų klinikinių požymių daugiau kaip savaitės veršeliams ir jauniems, negyviems galvijams. pooperacinio skausmo reljefas po veršelių atsikabinimo. papildomam gydymui ūminio mastito gydymui kartu su antibiotikų terapija. dogs:alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. pooperacinio skausmo ir uždegimo sumažinimas po ortopedinių ir minkštųjų audinių operacijų. horses:for use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. dėl skausmo, susijusio su arklių kolikomis, reljefas. mažinti uždegimus ir skausmo malšinimo tiek ūmus ir lėtinis raumenų ir kaulų sistemos sutrikimai. kiaulės: naudoti neinfekcinių judėjimo sutrikimų, siekiant sumažinti simptomų lameness ir uždegimas. už pagalbą pooperacinio skausmo, susijusios su nedideli minkštųjų audinių chirurgija, tokių kaip kastracija. už adjunctive terapijos gydymo puerperal kraujo užkrėtimas ir toxaemia (karvių mastito-metrito-agalaktijos sindromas) su tinkama antibiotikų terapija. jūrų kiaulytės:mažinimui lengvas ar vidutinio sunkumo pooperacinio skausmo, susijusios su minkštųjų audinių operacijos, pvz., vyrų kastracija.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

zoetis belgium sa - lokivetmab - kiti dermatologiniai preparatai, agentai, dermatitas, išskyrus kortikosteroidai - Šunys - Šunų atopinio dermatito klinikinių apraiškų gydymas.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pro. med. cs praha a.s. - nitrendipinas - tabletės - 20 mg; 10 mg - nitrendipine

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pharmaceutical works polpharma s.a. - kvinaprilis - plėvele dengtos tabletės - 40 mg; 20 mg; 10 mg - quinapril

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - naloksono hidrochloridas - injekcinis ar infuzinis tirpalas - 0,4 mg/ml - naloxone

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - abakaviras/lamivudinas - plėvele dengtos tabletės - 600 mg/300 mg - lamivudine and abacavir

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

zoetis belgium - bedinvetmab - analgetikai - Šunys - for the alleviation of pain associated with osteoarthritis in dogs.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mabxience research sl - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.